Investors Overview

We’re Delivering the Promise of Healthier Lives.

Our Company

Corporate Profile

CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug forms and delivery systems.

CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.

CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.

CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.

Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.

Learn More
Stock Today
USD - OTCQB - U.S. REGISTERED - DELAYED PRICE
Headquarters

CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone: (805) 410-9962
Fax: (805) 487-7163

We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.

Cure Pharmaceutical

Our Investor Presentation

View our latest investor presentation. Fiscal Year Ends: 12/31
Download
Media

Recent Videos

CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020

On the Investor Video Webcast, Rob Davidson, CEO of CURE, Nancy Duitch, CEO of wholly-owned subsidiary The Sera Labs and Chief Strategy Officer for the Company, and Mike Redard, CFO of CURE, presented on the Company’s strategic positioning among other topics and will address shareholder questions at the end of the webcast.

CBD, Cannabis and the Cannabiz

Nancy Duitch, Founder and CEO, Sera Labs; Rob Davidson, Founder and CEO, Cure Pharmaceutical Moderator: Brad Halpern, Chief Marketing Officer, Quality CBD, and City Councilmember, City of Westlake Village
In the news

Press Releases

CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)

May 12, 2022 |

CURE's Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)CCHMC to Seek Formulary...

read more

Management Team

Board of Directors

Nancy Duitch

Chief Strategic Officer and Director; CEO of Wholly owned subsidiary, The Sera Labs

Key Contacts 

Investor Relations

(805) 410-9962 ext. 4

investor@curepharma.com 

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
www.vstocktransfer.com

 

Auditors

RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022

 

Corporate Counsel

K&L Gates
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067